Accelerating therapeutic development and clinical trial readiness for STXBP1 and SYNGAP1 disorders

被引：2
|
作者：
Marotta, Nicolas [1 ,2 ,3 ,4 ]
Boland, Michael J. [2 ,3 ]
Prosser, Benjamin L. [2 ,3 ,4 ]
机构：
[1] Univ Penn, Perelman Sch Med, Dept Biochem & Biophys, Philadelphia, PA USA
[2] Univ Penn, Perelman Sch Med, Ctr Epilepsy & Neurodev Disorders ENDD, Philadelphia, PA 19104 USA
[3] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[4] Univ Penn, Perelman Sch Med, Penn Muscle Inst, Dept Physiol, Philadelphia, PA USA
来源：
CURRENT PROBLEMS IN PEDIATRIC AND ADOLESCENT HEALTH CARE | 2024年 / 54卷 / 08期
关键词：
MOUSE MODEL; MUTATIONS; ENCEPHALOPATHY; PHENOTYPES; GENE; EPILEPSY; AUTISM;
D O I：
10.1016/j.cppeds.2024.101576
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Gene-targeted therapies for genetic neurodevelopmental disorders (NDDs) are becoming a reality. The Center for Epilepsy and Neurodevelopmental Disorders (ENDD) is currently focused on the development of therapeutics for STXBP1 and SYNGAP1 disorders. Here we review the known clinical features of these disorders, highlight the biological role of STXBP1 and SYNGAP1, and discuss our current understanding of pathogenic mechanisms and therapeutic development. Finally, we provide our perspective as scientists and parents of children with NDDs, and comment on the current challenges for both clinical and basic science endeavors.
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Regulatory mechanisms and therapeutic potential of JAB1 in neurological development and disorders
    Yang, Yu
    Song, Ruying
    Gao, Yiming
    Yu, Hao
    Wang, Shuai
    MOLECULAR MEDICINE, 2023, 29 (01)
  • [42] Preclinical pharmacology and early clinical development of dopamine D1 positive allosteric modulators (D1PAMs) with therapeutic potential for neuropsychiatric disorders
    Svensson, K.
    Meltzer, H.
    Biglan, K.
    MOVEMENT DISORDERS, 2020, 35 : S124 - S124
  • [43] A rare case of pathogenic variant of c.784G>T, p.(Asp262Tyr) in exon 9 of the STXBP1 gene with clinical manifestation of developmental and epileptic encephalopathy 4
    Nonkulovski, D.
    Sofijanova, A.
    Muaremoska, L. Kanzoska
    Ademi, L.
    Jordanova, O.
    EPILEPSIA, 2023, 64 : 561 - 561
  • [44] Phenotype, genetics and natural history in 131 SEPN1-related myopathy patients: towards clinical trial readiness
    Villar-Quiles, R.
    von der Hagen, M.
    Quijano-Roy, S.
    Gonzalez, V.
    Donkervoort, S.
    de Visser, M.
    Fidzianska, A.
    Orlikowski, D.
    Goemans, N.
    Mayer, M.
    Merlini, L.
    Romero, N.
    Fardeau, M.
    Topaloglu, H.
    Metay, C.
    Richard, P.
    Estournet, B.
    Bonnemann, C.
    Schara, U.
    Ferreiro, A.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S81 - S82
  • [45] Development of Interactive Software for Bayesian Optimal Phase 1 Clinical Trial Design
    William F. Rosenberger
    Gerald C. Canfield
    Inna Perevozskaya
    Linda M. Haines
    Petr Hausner
    Drug information journal : DIJ / Drug Information Association, 2005, 39 (1): : 89 - 98
  • [46] Development of interactive software for Bayesian optimal phase 1 clinical trial design
    Rosenberger, WF
    Canfield, GC
    Perevozskaya, I
    Haines, LM
    Hausner, P
    DRUG INFORMATION JOURNAL, 2005, 39 (01): : 89 - 98
  • [47] Defining SOD1 ALS natural history to guide therapeutic clinical trial design
    Bali, Taha
    Self, Wade
    Liu, Jingxia
    Siddique, Teepu
    Wang, Leo H.
    Bird, Thomas D.
    Ratti, Elena
    Atassi, Nazem
    Boylan, Kevin B.
    Glass, Jonathan D.
    Maragakis, Nicholas J.
    Caress, James B.
    McCluskey, Leo F.
    Appel, Stanley H.
    Wymer, James P.
    Gibson, Summer
    Zinman, Lorne
    Mozaffar, Tahseen
    Callaghan, Brian
    McVey, April L.
    Jockel-Balsarotti, Jennifer
    Allred, Peggy
    Fisher, Elena R.
    Lopate, Glenn
    Pestronk, Alan
    Cudkowicz, Merit E.
    Miller, Timothy M.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (02): : 99 - 105
  • [48] Clinical and functional significance of CTHRC1 in melanoma cells: implications for therapeutic development
    Tang, L.
    Su, M.
    Dai, D.
    Martinka, M.
    Zhang, Y.
    Li, G.
    Zhou, Y.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 : 153 - 153
  • [49] TAPETORETINAL DEGENERATIONS AND DISORDERS OF LIPID-METABOLISM .1. CLINICAL, GENETIC, PATHOLOGICAL, AND THERAPEUTIC ASPECTS
    MERIN, S
    ACTA GENETICAE MEDICAE ET GEMELLOLOGIAE, 1974, 23 : 25 - 31
  • [50] 1st International Workshop on Clinical trial readiness for sarcoglycanopathies 15-16 November 2016, Evry, France
    Marsolier, Justine
    Laforet, Pascal
    Pegoraro, Elena
    Vissing, John
    Richard, Isabelle
    NEUROMUSCULAR DISORDERS, 2017, 27 (07) : 683 - 692
12345